You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

SGLT-2i

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

(NIS) on Sodium-glucose Co-transporter-2 Inhibitors Use in

Not yet recruiting
  • Diabetes Mellitus, Type 2
  • Sodium/glucose cotransporter-2 inhibitors (SGLT2i)
  • (no location specified)
May 22, 2023

Type 1 Diabetes Trial in La Jolla (Dapagliflozin 10 MG [Farxiga], REMD-477, Placebo)

Completed
  • Type 1 Diabetes
  • Dapagliflozin 10 MG [Farxiga]
  • +2 more
  • La Jolla, California
    UC San Diego Altman Clinical & Translational Research Institute
Jan 20, 2023

Transplant; Failure, Heart, Cardiac Allograft Vasculopathy, Rejection Heart Transplant Trial (SGLT2i)

Not yet recruiting
  • Transplant; Failure, Heart
  • +2 more
  • (no location specified)
Nov 19, 2023

Heart Failure, Reduced Ejection Fraction Heart Failure Trial in Damanhur (Empagliflozin 10 MG, Dapagliflozin 10 MG)

Recruiting
  • Heart Failure
  • Reduced Ejection Fraction Heart Failure
  • Empagliflozin 10 MG
  • Dapagliflozin 10 MG
  • DamanhÅ«r, Elbehairah, Egypt
    Damanhour Teaching Hospital, General Organization for Teaching H
Oct 3, 2023

Heart Failure With Reduced Ejection Fraction Trial in Chicago (SGLT2i, No SGLT2i)

Recruiting
  • Heart Failure With Reduced Ejection Fraction
  • Chicago, Illinois
    University of Chicago
Nov 11, 2022

Type 1 Diabetes Trial in Kuwait City (drug, other, procedure)

Not yet recruiting
  • Type 1 Diabetes
  • Liraglutide / Semaglutide
  • +4 more
  • Kuwait City, Al Asimah, Kuwait
    Dasman Diabetes Institute
Jan 8, 2023

Heart Failure With Reduced Ejection Fraction Trial in Porto (Sacubitril-valsartan, SGLT2 inhibitor)

Recruiting
  • Heart Failure With Reduced Ejection Fraction
  • Porto, Portugal
  • +3 more
Aug 9, 2023

Acute Decompensated Heart Failure Trial in Chicago (SGLT2i, No SGLT2i)

Not yet recruiting
  • Acute Decompensated Heart Failure
  • Chicago, Illinois
    University of Chicago
Jun 10, 2022

SGLT2-I Use in DFUD: a Delphi Study

Not yet recruiting
  • Diabetic Foot Ulcer
  • eDelphi method
  • (no location specified)
Aug 14, 2023

Fatty Liver, Nonalcoholic Trial (SGLT2 inhibitor)

Not yet recruiting
  • Fatty Liver, Nonalcoholic
  • SGLT2 inhibitor
  • (no location specified)
Oct 31, 2023

Sleep Apnea Trial in New Haven, Cleveland (Ertugliflozin 15 mg, Placebo)

Not yet recruiting
  • Sleep Apnea
  • Ertugliflozin 15 mg
  • Placebo
  • New Haven, Connecticut
  • +1 more
Jan 24, 2023

Heart Failure Trial (Finerenone, Empagliflozin)

Not yet recruiting
  • Heart Failure
  • (no location specified)
Sep 5, 2023

Diabetic Ketoacidosis From New SGLT2i: Can Genomics Estimate

Recruiting
  • Diabetes Type 2
  • +2 more
  • Genomic analysis
  • Toronto, Ontario, Canada
  • +1 more
Sep 1, 2022

ivness and Safety in Elderly Type 2 Diabetes Patients

Not yet recruiting
  • Type2Diabetes
  • SGLT2 inhibitor
  • Milan, Italy
    ASST FBF Sacco
Jul 25, 2022

Comparison of Type 2 Diabetes Pharmacotherapy Regimens

Recruiting
  • Type 2 Diabetes Mellitus
  • Cardiovascular Diseases
  • Oakland, California
  • +5 more
Oct 18, 2022

Diabetes, Type 1 Trial in Saint Louis (Dapagliflozin 10 MG [Farxiga], Biosense Breath Ketone Analyzer)

Not yet recruiting
  • Diabetes Mellitus, Type 1
  • Dapagliflozin 10 MG [Farxiga]
  • Biosense Breath Ketone Analyzer
  • Saint Louis, Missouri
    Washington University
Sep 12, 2022

Heart Failure Trial (SGLT2i, beta blocker, ARNI, MRA, MTD, Education-First)

Not yet recruiting
  • Heart Failure
  • SGLT2i, beta blocker, ARNI, MRA, MTD
  • Education-First
  • (no location specified)
Feb 9, 2023

Heart Failure With Preserved Ejection Fraction Trial in Philadelphia (Empagliflozin + Potassium Chloride, Empagliflozin +

Recruiting
  • Heart Failure With Preserved Ejection Fraction
  • Empagliflozin + Potassium Chloride
  • +2 more
  • Philadelphia, Pennsylvania
    University of Pennsylvania Health System
May 25, 2022

Called FLAMINgO to Learn More About Treatment Combination of

Active, not recruiting
  • Chronic Kidney Disease
  • Type 2 Diabetes
  • Finerenone (Kerendia, BAY94-8862)
  • Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
  • Whippany, New Jersey
    Bayer
Jan 19, 2023

Diabetes, SGLT-2i and GLP-1RA Therapies, Diffusion of Responsibility Trial (Intervention to address diffusion of responsibility,

Not yet recruiting
  • Diabetes
  • +3 more
  • Intervention to address diffusion of responsibility
  • Intervention to address diffusion of responsibility + simplification of prescribing
  • (no location specified)
Jul 14, 2022

Diabetes, Type 1 Trial in Aurora, London, Toronto (Dapagliflozin 5mg, Placebo)

Recruiting
  • Diabetes Mellitus, Type 1
  • Dapagliflozin 5mg
  • Placebo
  • Aurora, Colorado
  • +2 more
Oct 31, 2022

Diabetic Kidney Disease Trial in Herlev (ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide,

Recruiting
  • Diabetic Kidney Disease
  • ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib
  • Herlev, Denmark
    Department of Nephrology, Herlev and Gentofte Hospital
May 31, 2023

SGLT2-I in Diabetic AMI (SGLT2-I AMI PROTECT Study)

Recruiting
  • Diabetes Mellitus
  • Acute Coronary Syndrome
    • Aalst, Belgium
    • +6 more
    Mar 2, 2022

    IgA Nephropathy, Immunoglobulin A Nephropathy Trial (Atrasentan, Placebo)

    Not yet recruiting
    • IgA Nephropathy
    • Immunoglobulin A Nephropathy
    • (no location specified)
    Apr 27, 2023

    Chronic Kidney Disease, Diabetes, Type 2, Hypertension Trial in Genova (Dapagliflozin 10mg Tab, Placebo)

    Recruiting
    • Chronic Kidney Disease
    • +2 more
    • Dapagliflozin 10mg Tab
    • Placebo
    • Genova, GE, Italy
      IRCCS Ospedale Policlinico San Martino
    Aug 10, 2023